Skip to main content

Table 1 Demographic and clinical characteristics of treatment-naive Mexican PLWH

From: Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV

Variables

 

Demographics

 

Gender, n (%)

 

 Male

99 (99.0%)

 Female

1 (1.0%)

Age (years), median (min–max)

28 (18–66)

Marital status, n (%)

 

 Single

77 (77.0%)

 Married

4 (4.0%)

 Divorced

2 (2.0%)

 Free union

16 (16.0%)

 Widowed

1 (1.0%)

Literacy, n (%)1

 

 Primary school

3 (3.2%)

 Junior High school

7 (7.4%)

 High school

26 (27.4%)

 Technical qualification

7 (7.4%)

 Degree

50 (52.6%)

 Postgraduate

2 (2.1%)

Employment, n (%)

 

 Employed

86 (86.0%)

 Unemployed

1 (1.0%)

 Student

13 (13.0%)

HIV

 

 CD4 count (cell/mm3), median [IQR]2

150[68.0–355.78]

 CD4 cell count (%), mean (SD)3

11.7 (7.8)

 Plasma viral load (copies/mL)2, median [IQR]

99,551 [24256.75–248,259.25]

 Plasma viral load (log copies/mL)2, median [IQR]

4.99 [4.39–5.40]

 HIV acquisition risk factor, n (%)4

 

 Men who have sex with men

74 (74.7%)

 Heterosexual

11 (11.1%)

 Bisexual

14 (14.1%)

HIV-1 subtype, n (%)

 

 B

94 (97.9%)

 Non-B

2 (2.1%)

ART

 

Time Dx to ART initiation (days), median [IQR]2

38.5 [20.8–60.5]

First-line regimen, n (%)2

 

 TDF-FTC-EFV

49 (50.0%)

 TDF-FTC-ATVr

18 (18.4%)

 ABC-3TC-ATVr

15 (15.3%)

 ABC-3TC-EFV

12 (12.2%)

 ABC-TDF-ATVr

1 (1.0%)

 TDF-FTC-LPVr

1 (1.0%)

 TDF-3TC-EFV

1 (1.0%)

 ABC-3TC-DTG

1 (1.0%)

  1. ART antiretroviral therapy, TDF Tenofovir, FTC Emtricitabine, EFV Efavirenz, ATV/r Atazanavir/ritonavir, ABC Abacavir, 3TC Lamivudine, LPV/r Lopinavir/ritonavir, DTG Dolutegravir, n number, % percentage, IQR = interquartile range, HIV Human Immunodeficiency Virus, Dx diagnosis
  2. 1Data on literacy was missing for 5 individuals
  3. 2Data was missing for 2 individuals
  4. 3Data on CD4 cell count (%) was missing for 27 individuals
  5. 4Data was missing for 1 individual